Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Technical Presentation (July 2024)
23 slides from Cognition Therapeutics's technical presentation, Jul 29, 2024
Slide 1: Results from the Proof-of-Concept Phase 2 'SHINE' Study of CT1812
Results from the Proof-of-Concept Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease July 29, 2024
Slide 2: Forward-looking Statements
Forward-looking Statements FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate t
Slide 3: Alzheimer's Disease and CGTX
Alzheimer’s Disease and CGTX THE CHALLENGE THE OPPORTUNITY Despite 35 years of research based on the Strong scientific evidence supports the Amyloid Amyloid Cascade Hypothesis, there are only Oligomer Hypothesis, ie, that oligomers—not TWO approved therapies and major unmet plaques—are the MOST NEUR
Slide 4: CT1812 Background
CT1812 Background Brief history of CT1812 development • Candidate identified by Cognition Therapeutics team via a screen established to identify molecules that protect neurons from the toxicity of Aβ oligomers • Long history of Cognition research and publications has demonstrated that CT1812 can red
Slide 5: Summary of COG0201 SHINE Results
Summary of COG0201 SHINE Results Compelling evidence to advance into next phase of study • COG0201 SHINE: FPI October 2018, LPO May 2024 • Favorable treatment differences versus placebo with both 100mg and 300mg dose groups on all key cognitive outcome measures • CT1812 treatment resulted in slowing
Slide 6: Phase 2 Safety and Efficacy Study in Adults with Mild-to-Moderate Alzheimer's Disease
Phase 2 Safety and Efficacy Study in Adults with Mild-to- Moderate Alzheimer’s Disease SHINE COG0201 study (NCT03507790) partially funded by $31M NIA grant R01AG058660 8
Slide 7: COG0201 SHINE Participant Disposition
COG0201 SHINE Participant Disposition 9
Slide 8: COG0201 SHINE Baseline Characteristics
COG0201 SHINE Baseline Characteristics 10
Slide 9: Cognitive Endpoints: ADAS-Cog 11 and MMSE
Cognitive Endpoints: ADAS-Cog 11 and MMSE 39% slowing of ADAS-Cog 11 decline at six months vs baseline compared to placebo, magnitude of effect similar to approved MAbs ADAS-Cog 11 MMSE Pooled vs. pbo: Pooled vs. pbo: 70% slowing 39% slowing a) Pooled 100mg and 300mg group vs placebo p=0.3009. b) Po
Slide 10: Cognitive Endpoints: ADAS-Cog 13, Cognitive Composite
Cognitive Endpoints: ADAS-Cog 13, Cognitive Composite Consistent results across multiple cognitive endpoints ADAS-Cog 13 Cognitive Composite Pooled vs. pbo: 50% slowing Pooled vs. pbo: 39% slowing 12
Slide 11: Additional Cognitive and Functional Measures
Additional Cognitive and Functional Measures Consistent though not significant results; likely requires longer-term trial ADCS-ADL ADCS-CGIC 13
Slide 12: Summary of Exploratory Outcomes
Summary of Exploratory Outcomes Trending positive across most cognitive and functional measures Time ADAS- ADAS- ADCS- ADCS-ADL Cognitive MMSE Frame Cog 11 Cog 13 CGIC Composite CT1812 Day 98 Δ -1.79 Δ -2.16 Δ 0.11 Δ 0.05 Δ 0.05 Δ 0.97 100mg p = 0.0430 p =0.0376 p = 0.6288 p = 0.9644 p = 0.3920 p =
Slide 13: Summary Exploratory Outcomes - Percent Slowing Day 182
Summary Exploratory Outcomes - Percent Slowing Day 182 Effect as large or larger than approved MAbs and some experimental therapeutics ADAS-Cog 11 ADAS-Cog 13 MMSE Cognitive Composite ADCS-ADL ADCS-CGIC CT1812 100mg 36% 42% 47% 40% 28% 32% CT1812 300mg 40% 36% 93% 60% 23% 24% CT1812 Pooled 39% 39% 7
Slide 14: Safety Findings
Safety Findings XCOGNITION” Therapeutics
Slide 15: COG0201 SHINE TEAE Summary
COG0201 SHINE TEAE Summary Adverse events are well balanced and mostly mild or moderate in nature 17
Slide 16: Most Frequent AEs by system organ class and preferred term
Most Frequent AEs by system organ class and preferred term 18
Slide 17: COG0201 SHINE Safety Conclusions
COG0201 SHINE Safety Conclusions Results consistent with previous clinical trials • CT1812 demonstrated favorable safety and tolerability profile • Most AEs were mild or moderate • Percentage of subjects experiencing any AE was similar between the pooled CT1812 treatment group (76.5%) and the placeb
Slide 18: Exploratory Biomarker Findings
Exploratory Biomarker Findings
Slide 19: Biomarker Findings
Biomarker Findings Biomarkers of Synaptic Function • CSF samples at screening and Day 182 (optional), available in ~50% of mITT population • Neurofilament Light Chain - Significant (p<0.05) reduction relative to placebo for 300mg dose - Reduction trend (p<0.10) for 100mg dose - Supports potential sl
Slide 20: Signal of Impact on Neurodegeneration Based on NfL Change
Signal of Impact on Neurodegeneration Based on NfL Change Reductions in CSF NfL relative to placebo consistent with slowing neurodegeneration 22
Slide 21: What we have Learned from POC SHINE Phase 2 Trial
What we have Learned from POC SHINE Phase 2 Trial Novel mechanism in oral, once daily form may be important for treatment options • CT1812 showed favorable safety and tolerability profile with most AEs mild or moderate • Results of study inform dosing for next phase of study - 100mg dose provided si
Slide 22: Science & Clinical Medicine Advance Through the Work of Many
Science & Clinical Medicine Advance Through the Work of Many CGTX wishes to acknowledge and thank those who made this trial possible • Participants and their study partners • Clinical investigators and site staff • US and International Clinical research partners • Cognition clinical operations team
Slide 23: Thank You
Thank You Lisa Ricciardi President & CEO [email protected] Tony Caggiano, MD, PhD CMO and Head of R&D [email protected] John Doyle Chief Financial Officer [email protected]
Cognition Therapeutics — Technical Presentation (July 2024) on 6ix